Efectos adversos asociados al uso de hidroxiurea en pacientes con policitemia vera en el Hospital Doctor Salvador Bienvenido Gautier 2017- 2019

Abstract

La policitemia Vera (PV) es una neoplasia mieloproliferativa crónica y progresiva caracterizada por un aumento anormal primario, impulsado por clonación en la masa de glóbulos rojos y aumentos en los recuentos de glóbulos blancos y plaquetas. La hidroxiurea (HU) se encuentra entre los tratamientos citorreductores más utilizados para la policitemia vera (PV), pero la investigación previa y la experiencia clínica sugieren que no todos los pacientes responden de manera óptima, constante o duradera al tratamiento con hidroxiurea. La hidroxiurea consigue un control adecuado de la enfermedad en el 90 por ciento de pacientes. Suele tolerarse bien, no obstante, un 11 por ciento de los pacientes presenta intolerancia generalmente en forma de úlceras cutáneas o intolerancia gastrointestinal. Este estudio se realizó en el hospital Dr. Salvador B. Gautier con la finalidad de determinar la frecuencia de los efectos adversos asociados al uso de hidroxiurea en pacientes con policitemia vera en el servicio de Hematología, 2017-2019.

Polycythemia vera (PV) is a chronic and progressive myeloproliferative neoplasm characterized by a primary abnormal increase, driven by cloning in the mass of red blood cells and increases in white blood cell and platelet counts. Hydroxyurea (HU) is among the most commonly used cytoreductive treatments for polycythemia vera (PV), but previous research and clinical experience suggest that not all patients respond optimally, steadily or permanently to hydroxyurea treatment. Hydroxyurea achieves adequate control of the disease in 90 percent of patients. It is usually well tolerated, however, 11 percent of patients have intolerance usually in the form of skin ulcers or gastrointestinal intolerance. This study was conducted at the Dr. Salvador B. Gautier hospital in order to determine the frequency of adverse effects associated with the use of hydroxyurea in patients with polycythemia vera in the Hematology department, 2017-2019.

Polycythemia Vera (PV) is a chronic and progressive myeloproliferative neoplasm characterized by a primary abnormal increase, driven by cloning in the mass of red blood cells and increases in white blood cell and platelet counts. Hydroxyurea (HU) is among the most commonly used cytoreductive treatments for polycythemia vera (PV), but previous research and clinical experience suggest that not all patients respond optimally, steadily or permanently to hydroxyurea treatment. Hydroxyurea achieves adequate control of the disease in 90 percent of patients. It is usually well tolerated, however, 11 percent of patients have intolerance usually in the form of skin ulcers or gastrointestinal intolerance. This study was conducted at the Dr. Salvador B. Gautier hospital in order to determine the frequency of adverse effects associated with the use of hydroxyurea in patients with polycythemia vera in the Hematology department, 2017-2019.